For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1830/Global-Inflammatory-Bowel-Diseases-(IBD)-Drug-Market-Forecast-2017-2027
Global Animal Antibiotics and Antimicrobials Market (2017-2022) AzothAnalytics
The global Animal Antibiotics & Antimicrobials industry has been driven by the rising demand for animal derived food products and increasing healthcare expenditure on pets due to rising pet ownership. Globally, the growth in Animal Antibiotics & Antimicrobials market is driven by growing middle class population.
http://azothanalytics.com/report/healthcare-pharma/global-animal-antibiotics-and-antimicrobials-market-analysis-product-type-delivery-type-type-of-animals-company-analysis-regional-and-country-analysis-2017-2022-r14142
Global Antibacterial Drugs Market 2017-2027Visiongain
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027
Global monoclonal antibodies market report 2017Chlue Reseach
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
Content
McAbs Market
Biosimilars
Antineoplastic drugs
Autoimmune diseases
Ophthalmic remedy
PD-1 and PD-L1 McAbs
McAbs approved by FDA
Next Generation Antibody Therapies World Industry 2014-2024Visiongain
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1210/Next-Generation-Antibody-Therapies-World-Industry-and-Market-2014-2024
Migraine Pipeline Drugs Market Assessment– Forecast to 2022AzothAnalytics
The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.
Global Animal Antibiotics and Antimicrobials Market (2017-2022) AzothAnalytics
The global Animal Antibiotics & Antimicrobials industry has been driven by the rising demand for animal derived food products and increasing healthcare expenditure on pets due to rising pet ownership. Globally, the growth in Animal Antibiotics & Antimicrobials market is driven by growing middle class population.
http://azothanalytics.com/report/healthcare-pharma/global-animal-antibiotics-and-antimicrobials-market-analysis-product-type-delivery-type-type-of-animals-company-analysis-regional-and-country-analysis-2017-2022-r14142
Global Antibacterial Drugs Market 2017-2027Visiongain
For a report overview of this report please contact sara.peerun@visiongainglobal.com
(+44 (0) 20 7336 6100) or refer to our website:
https://www.visiongain.com/
https://www.visiongain.com/Report/1821/Global-Antibacterial-Drugs-Market-2017-2027
Global monoclonal antibodies market report 2017Chlue Reseach
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
Content
McAbs Market
Biosimilars
Antineoplastic drugs
Autoimmune diseases
Ophthalmic remedy
PD-1 and PD-L1 McAbs
McAbs approved by FDA
Next Generation Antibody Therapies World Industry 2014-2024Visiongain
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1210/Next-Generation-Antibody-Therapies-World-Industry-and-Market-2014-2024
Migraine Pipeline Drugs Market Assessment– Forecast to 2022AzothAnalytics
The report presents the market potential of seven major pipeline drugs meant for the treatment of migraine. These seven drugs that fall in the various categories of Ergotamines, Anti 5-HT Receptor Agonists and Anti-CGRPs by mechanism of action have been recognized as being clinically effective in migraine treatment. Expected to be launched in the market within the next 4-5 years, these seven potential drugs are likely to bring about major changes in the way migraine is treated globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.Visit us: http://azothanalytics.com/report/healthcare-pharma/global-antifungal-drugs-market-analysis-by-drug-class-azoles-echinocandins-polyenes-others-by-therapeutic-indications-candidiasis-aspergillosis-dermatophytosis-others-by-region-by-country-2019-edition-opportunities-and-forecast-2013-2023-r28194
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Global Intravenous Immunoglobulin Market (By Application, Types and Geography...Allied Market Research
IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.
Biosensors have applications in medical testing, food toxicity detection, industrial processing and monitoring, agricultural applications, and environmental pollution control. Biosensors are essentially devices capable of fast detection and are ideal for applications that demand low-cost, quick and easy, portable solutions. Biosensors are used to ensure quality and safety of products and detection of microbial pathogens and toxins in food cost-efficiently. Point-of-care testing (POCT) is the most proficient area for biosensor application.
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...Reports Corner
GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan.
https://www.reportscorner.com/reports/20855/Immunoglobulins-Market-to-2019---Demand-in-Primary-Immunodeficiency-(PI)-and-Chronic-Inflammatory-Demyelinating-Polyneuropathy-(CIDP)-Potentially-Supplemented-by-Approvals-for-Alzheimers-Disease/
Global Hepatitis B Virus [HBV] Treatment Market: Opportunities and Forecast (...Matloob Hasan
The global Hepatitis B treatment market growth is backed by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infection, improving surveillance and diagnostic facilities, significant number drugs in pipeline with better efficacy coupled with emerging vaccines with lower dosage and better effectiveness. Moreover, the global market growth is driven by the rising global healthcare expenditure, healthcare infrastructure development and changing lifestyle is expected to supplement the market growth during the forecast period.
Global glycobiology market size, share & market forecast 2025TechSci Research
According to www.techsciresearch.com latest Report- Global glycobiology market is expected to grow at a formidable rate during the forecast period. The global glycobiology market is driven by the growing prevalence of chronic diseases such as cancer, diabetics, renal diseases, among others, which has increased the demand for personalized medicines
Report URL- https://www.techsciresearch.com/report/glycobiology-market/4635.html
Aminoglycosides Market Analysis By Drug, Mode of Administration, Application...Grand View Research
Aminoglycosides Market Analysis By Drug (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin), By Mode of Administration (Feed, Injectables (Parenteral), Intra-mammary, Topical, Oral), By Application (Veterinary, Skin, Respiratory, UTI & Pelvic Disease, Neonatal Sepsis) And Segment Forecasts To 2022
Precision Medicine Market – Analysis and Forecast (2017-2026)BIS Research Inc.
The global precision medicine market is expected to be $141.7 billion by 2026. The market growth is attributed to the adoption of early stage treatments, increased number of adverse drug reactions cases, prevalence of chronic diseases, and advancement in genetic science, among others.
Our consulting and research services have been tailored for your requirements and your company as a way to explore growth plans and strategies. We do not stick to the one-size-fits-all approach.
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Probiotics Market was estimated at USD 63.70 Billion units in 2021, are estimated to gain a revised size of USD 105.68 Billion by 2028 growing at a CAGR of 7.5% globally.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Antifungal Drugs Market. The report analyses the Antifungal Drugs Market By Drug Type (Azoles, Echinocandins, Polyenes, Others), By Therapeutic Indications (Candidiasis, Aspergillosis, Dermatophytosis, Others). The report analyses the Antifungal Drugs Market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, China, Japan, India) for the historical period of 2013-2017 and the forecast period of 2018-2023.Visit us: http://azothanalytics.com/report/healthcare-pharma/global-antifungal-drugs-market-analysis-by-drug-class-azoles-echinocandins-polyenes-others-by-therapeutic-indications-candidiasis-aspergillosis-dermatophytosis-others-by-region-by-country-2019-edition-opportunities-and-forecast-2013-2023-r28194
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1279/Ophthalmic-Drugs-Market-Forecast-2014-2024
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Global Intravenous Immunoglobulin Market (By Application, Types and Geography...Allied Market Research
IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.
Biosensors have applications in medical testing, food toxicity detection, industrial processing and monitoring, agricultural applications, and environmental pollution control. Biosensors are essentially devices capable of fast detection and are ideal for applications that demand low-cost, quick and easy, portable solutions. Biosensors are used to ensure quality and safety of products and detection of microbial pathogens and toxins in food cost-efficiently. Point-of-care testing (POCT) is the most proficient area for biosensor application.
Immunoglobulins market to 2019 demand in primary immunodeficiency (pi) and ...Reports Corner
GBI Research's report "Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer's Disease" provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan.
https://www.reportscorner.com/reports/20855/Immunoglobulins-Market-to-2019---Demand-in-Primary-Immunodeficiency-(PI)-and-Chronic-Inflammatory-Demyelinating-Polyneuropathy-(CIDP)-Potentially-Supplemented-by-Approvals-for-Alzheimers-Disease/
Global Hepatitis B Virus [HBV] Treatment Market: Opportunities and Forecast (...Matloob Hasan
The global Hepatitis B treatment market growth is backed by the increasing number of patients diagnosed with Chronic Hepatitis B which results in severe complications, rising awareness about the consequences of viral infection, rigorous efforts to eliminate the viral infection, improving surveillance and diagnostic facilities, significant number drugs in pipeline with better efficacy coupled with emerging vaccines with lower dosage and better effectiveness. Moreover, the global market growth is driven by the rising global healthcare expenditure, healthcare infrastructure development and changing lifestyle is expected to supplement the market growth during the forecast period.
Global glycobiology market size, share & market forecast 2025TechSci Research
According to www.techsciresearch.com latest Report- Global glycobiology market is expected to grow at a formidable rate during the forecast period. The global glycobiology market is driven by the growing prevalence of chronic diseases such as cancer, diabetics, renal diseases, among others, which has increased the demand for personalized medicines
Report URL- https://www.techsciresearch.com/report/glycobiology-market/4635.html
Aminoglycosides Market Analysis By Drug, Mode of Administration, Application...Grand View Research
Aminoglycosides Market Analysis By Drug (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin), By Mode of Administration (Feed, Injectables (Parenteral), Intra-mammary, Topical, Oral), By Application (Veterinary, Skin, Respiratory, UTI & Pelvic Disease, Neonatal Sepsis) And Segment Forecasts To 2022
Precision Medicine Market – Analysis and Forecast (2017-2026)BIS Research Inc.
The global precision medicine market is expected to be $141.7 billion by 2026. The market growth is attributed to the adoption of early stage treatments, increased number of adverse drug reactions cases, prevalence of chronic diseases, and advancement in genetic science, among others.
Our consulting and research services have been tailored for your requirements and your company as a way to explore growth plans and strategies. We do not stick to the one-size-fits-all approach.
The Biologics Market was worth USD 267.58 billion in 2014 and is expected to reach approximately USD 373.66 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 3.78% during the forecast period. Biologics are medicates as hereditarily built proteins, got from human qualities. According to the US FDA, biologics can be made out of sugars, proteins, or nucleic acids or complex blends of these substances, or might live elements, for example, cells and tissues. The biologic medications are taken from an assortment of regular sources, for example, people, creatures, or microorganisms and comprise of items, for example, antibodies, blood and blood parts, allergenic, substantial cells, quality treatment, tissues, and recombinant remedial proteins. Propelled biotechnology strategies and complex procedures are utilized to produce biologics. They are at the cutting edge of biomedical research.
Probiotics Market was estimated at USD 63.70 Billion units in 2021, are estimated to gain a revised size of USD 105.68 Billion by 2028 growing at a CAGR of 7.5% globally.
Biological Safety Testing Market Size, Product Analysis and Applications, 201...Signitech
The global biological safety testing market size was valued at USD 2.20 billion in 2016 and is anticipated to exhibit a CAGR of 12.2% during the forecast period.
Personalized Medicine Market is Projected to Reach $2,452.5 Billion by 2022Grand View Research
Personalized Medicine (PM) Market Analysis By Product (PM Diagnostics, PM Therapeutics, Personalized Medical Care, Personalized Nutrition & Wellness) And Segment Forecasts To 2022
Global Animal Antibiotics and Antimicrobials Market (2017-2022) geeti chauhan
Globally, the growth of the Animal Antibiotics & Antimicrobials market is driven by increasing trend of pet humanization resulting in higher pet ownerships coupled with increasing animal health awareness, significant improvement in animal healthcare facilities and rising demand for animal derived food products which is propelling the growth of the Animal Antibiotics & Antimicrobials market worldwide. Moreover, the market is getting consolidated in terms of recent mergers and acquisition where the major players are strengthening their product portfolios and expanding their geographical reach.
According to Azoth Analytics research report, "Global Animal Antibiotics and Antimicrobials Market Analysis - Product Type, Delivery Type, Type of Animals, Company Analysis, Regional and Country Analysis (2017-2022) – By Product Type (Penicillins, Fluoroguinolones, Aminoglycosides, Tetracyclines, Fluoroguinolones, Macrolides, Sulfonamides, Lincosamides, Cephalosporins, Others), By Delivery Type (Premixes, Oral Powder, Oral Solution, Injections and Others), By Type of Animals (Farm Animals, Companion Animals)”, is projected to exhibit a CAGR of over ~4.24% during 2017 – 2022, largely driven by the increase in spending of pet owners towards their pet health, growing demand for animal derived protein resulting in increasing farm sizes and animal population. It has been estimated by OECD that the consumption of meat will be 373 million metric tons by 2030 and 465 million tons by 2050 resulting in higher meat production. Many countries are shifting their focus to integrate meat production as a part of mainstream economic activity resulting in expanding farm sizes for the purpose of exports.
Generally, the risk of spread of zoonotic diseases increases with rising pet ownership and growing demand for animal derived food products resulting in the increasing usage of antibiotics & antimicrobials to prevent the further spread of the disease.
APAC is predicted to grow at higher rate during the year 2017-2012F, which is mainly driven by the increase in ownership of pets along with the rising demand for animal derived food products and growing preference for better animal healthcare products.
Tetracycline accounts for 43.85% of global animal antibiotics & antimicrobials market and anticipated to grow at significant rate during forecast period owing to the applicability to farm as well as companion animals along with the multi-purpose usage. Premixes accounts for more than x% of the total animal antibiotics & antimicrobials market and expected to continue dominating the global market during the forecast period with positive growth rate.
Taurus Zodiac Sign_ Personality Traits and Sign Dates.pptxmy Pandit
Explore the world of the Taurus zodiac sign. Learn about their stability, determination, and appreciation for beauty. Discover how Taureans' grounded nature and hardworking mindset define their unique personality.
As a business owner in Delaware, staying on top of your tax obligations is paramount, especially with the annual deadline for Delaware Franchise Tax looming on March 1. One such obligation is the annual Delaware Franchise Tax, which serves as a crucial requirement for maintaining your company’s legal standing within the state. While the prospect of handling tax matters may seem daunting, rest assured that the process can be straightforward with the right guidance. In this comprehensive guide, we’ll walk you through the steps of filing your Delaware Franchise Tax and provide insights to help you navigate the process effectively.
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...BBPMedia1
Marvin neemt je in deze presentatie mee in de voordelen van non-endemic advertising op retail media netwerken. Hij brengt ook de uitdagingen in beeld die de markt op dit moment heeft op het gebied van retail media voor niet-leveranciers.
Retail media wordt gezien als het nieuwe advertising-medium en ook mediabureaus richten massaal retail media-afdelingen op. Merken die niet in de betreffende winkel liggen staan ook nog niet in de rij om op de retail media netwerken te adverteren. Marvin belicht de uitdagingen die er zijn om echt aansluiting te vinden op die markt van non-endemic advertising.
India Orthopedic Devices Market: Unlocking Growth Secrets, Trends and Develop...Kumar Satyam
According to TechSci Research report, “India Orthopedic Devices Market -Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the India Orthopedic Devices Market stood at USD 1,280.54 Million in 2024 and is anticipated to grow with a CAGR of 7.84% in the forecast period, 2026-2030F. The India Orthopedic Devices Market is being driven by several factors. The most prominent ones include an increase in the elderly population, who are more prone to orthopedic conditions such as osteoporosis and arthritis. Moreover, the rise in sports injuries and road accidents are also contributing to the demand for orthopedic devices. Advances in technology and the introduction of innovative implants and prosthetics have further propelled the market growth. Additionally, government initiatives aimed at improving healthcare infrastructure and the increasing prevalence of lifestyle diseases have led to an upward trend in orthopedic surgeries, thereby fueling the market demand for these devices.
2. www.visiongain.com
Contents
1. Report Overview
1.1 World IBD Drugs Market: Overview of Findings
1.2 Why You Should Read This Report
1.3 How the Study Delivers
1.4 Main Questions Covered in the Analysis
1.5 Who Is This Report For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to the Inflammatory Bowel Disease Drug Market
2.1 What is Inflammatory Bowel Disease (IBD)?
2.2 Classification of IBD
2.3 Symptoms and Diagnosis of IBD
2.4 Multifactorial Causes of IBD
2.5 How Common is IBD?
2.6 What Are the Treatment Options for IBD?
2.6.1 Aminosalicylates – The Most Common therapy
2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?
2.6.3 Corticosteroids – Uptake from Uceris?
2.6.4 Immunomodulators – Slow to Act?
2.6.5 Monoclonal Antibodies – Not cost-effective?
2.7 Treatment Goals for IBD – Treat-to-Target Approach?
2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?
3. www.visiongain.com
Contents
3. The World Inflammatory Bowel Disease Drug Market, 2017-2027
3.1 The Inflammatory Bowel Disease Market in 2016 and 2017
3.2 Forecast 2017-2027: Impacted by Biosimilars?
3.3 Biologic Therapies Forecast 2017-2027 – Driving the Market
3.4 Aminosalicylates Forecast 2017-2027: The Work Horse of IBD Market
3.5 Antibiotics Forecast 2017-2027: Growing Despite Challenges
3.6 Corticosteroids Forecast 2017-2027: Driven by Uceris
3.7 Immunomodulators Forecast 2017-2027 – Will Slowly Lose Market Share
4. Market Prospects for Leading IBD Drugs, 2017-2027
4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period
4.1.1 Humira: Forecast and Analysis, 2017-2027
4.2 Remicade (Janssen Biotech) – Will Slowly be Eroded by Biosimilars
4.2.1 Remicade: Forecast and Analysis, 2017-2027
4.3 Asacol (Allergan) – Threat from Generic Competition
4.3.1 Asacol: Forecast and Analysis, 2017-2027
4.4 Pentasa (Shire) – Differentiated by Its Delivery System
4.4.1 Pentasa: Forecast and Analysis, 2017-2027
4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?
4.5.1 Lialda: Forecast and Analysis, 2017-2027
4.6 Tysabri (Perrigo) – Still Protected by Patent
4.6.1 Tysabri: Forecast and Analysis, 2017-2027
4.7 Xifaxan (Valeant) – Still Growing Significantly
4.7.1 Xifaxan: Forecast and Analysis, 2017-2027
4.8 Cimzia (UCB) – How Will It Fare Against Biosimilars?
4.8.1 Cimzia: Forecast and Analysis, 2017-2027
4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?
4.9.1 Entocort: Forecast and Analysis, 2017-2027
4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?
4.10.1 Neoral: Forecast and Analysis, 2017-2027
4. www.visiongain.com
Contents
4.11 Medrol (Pfizer) – Another Leading Steroid
4.11.1 Medrol: Forecast and Analysis, 2017-2027
4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?
4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027
4.13 Apriso (Valeant) – Challenger to Asacol?
4.13.1 Apriso: Forecast and Analysis, 2017-2027
4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market
4.14.1 Azulfidine: Forecast and Analysis, 2017-2027
4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment
4.15.1 Entyvio: Forecast and Analysis, 2017-2027
4.16 Simponi (Janssen Biotech) – Rising Star for the Market?
4.16.1 Simponi: Forecast and Analysis, 2017-2027
4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System
4.17.1 Uceris: Forecast and Analysis, 2017-2027
5. Leading National Markets: Sales Outlooks, 2017-2027
5.1 IBD Drugs - Leading National Markets 2016
5.2 The US IBD Drug Market, 2017-2017 – The World Leader
5.3 The Japanese IBD Drug Market, 2017-2027 – Growing Significantly?
5.4 The EU-5 IBD Drug Market, 2017-2027 – Driven by the UK
5.4.1 The German IBD Drug Market, 2017-2027
5.4.2 The French IBD Drug Market, 2017-2027
5.4.3 The UK IBD Drug Market, 2017-2027
5.4.4 The Spanish IBD Drug Market, 2017-2027
5.4.5 The Italian IBD Drug Market, 2017-2027
5.5 IBD Drug Markets in BRIC Countries – Taking More Market Share
5.5.1 The Brazilian IBD Drug Market, 2017-2027
5.5.2 The Russian IBD Drug Market, 2017-2027
5.5.3 The Indian Drug Market, 2017-2027
5.5.4 The Chinese IBD Drug Market, 2017-2027
5. www.visiongain.com
Contents
6. The R&D Pipeline for Inflammatory Bowel Disease, 2016
6.1 Top Marketed and pipeline products – Launch dates and Patent expiry
6.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation
6.2.1 CyCol (Sigmoid Pharma)
6.2.2 PF-04236921 (Pfizer)
6.2.3 QAX 576 (Novartis)
6.2.4 TNF Kinoid (Neovacs)
6.2.5 Vidofludimus (4SC) – Suspended
6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
6.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue
6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
6.3.3 MEDI 7183/AMG 181 (AstraZeneca)
6.3.4 Etrolizumab (Roche)
6.3.5 PF-00547659 (Pfizer)
6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
6.4 TNF-α Inhibitors – a Specific Target
6.4.1 AVX-470 (Avaxia Biologics)
6.4.2 Ozoralizumab (ALX-0061, Ablynx)
6.5 Stem Cell Therapies – Basis for a Cure?
6.5.1 Ovasave (TxCell)
6.5.2 MultiStem (Athersys and Pfizer)
6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
6.5.4 Cx601 (TiGenix)
6.6 JAK Inhibitors – New Target Pathway
6.6.1 JNJ-54781532 (Janssen)
6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
6.7 Toll-like Receptor Agonists
6.7.1 BL-7040 (BioLineRX)
6.7.2 Kappaproct (InDex Pharmaceuticals)
6. www.visiongain.com
Contents
6.8 Other Classes of Agent
6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
6.8.2 GLPG0974 (Galapagos)
6.8.3 RPC1063 (Receptos/now Celgene)
6.8.4 SGX203 (Soligenix)
6.8.5 Mongersen (GED-0301, Celgene)
6.8.6 Tetomilast (OPC-6535, Otsuka)
6.8.7 Laquinimod (Active Biotech)
6.8.8 RHB-104 (RedHill Biopharma)
6.8.9 Ozanimod (Celgene)
6.8.10 GED-0301 (Celgene)
6.9 Biosimilar Candidates – Promising Competitors of Leading Biologics
6.9.1 Adalimumab Biosimilars
6.9.2 Infliximab Biosimilars
7. Drivers and Restraints in the Inflammatory Bowel Disease Drug
Industry and Market, 2016
7.1 SWOT and STEP Analyses of the IBD Drugs Market
7.2 What Factors Will Stimulate the IBD Market?
7.2.1 Increasing Disease Incidence in Most National Markets
7.2.2 Better Diagnosis – Early Referrals
7.2.3 Delivery Systems Improve Existing Drugs
7.2.4 Biological Drugs – Driving the Market Significantly
7.2.5 Socioeconomic Costs of IBD
7.3 What Factors Will Restrain the Market?
7.3.1 Lack of Understanding of Disease Aetiology
7.3.2 Compliance – Frequent Dosing is Inconvenient
7.3.3 Limitations of Biologics – Side Effect Profiles
7.3.4 The Possible Development of Alternative Treatments
7.3.5 Surgery – Treatment for Recalcitrant IBD
7. www.visiongain.com
Contents
7.3.6 Health Care Cost Containment
8. Leading Companies in the IBD Pharmaceuticals Market, 2016
8.1 The Largest Companies by Revenue
8.1.1 AbbVie
8.1.2 Janssen Biotech
8.1.3 Allergan
8.1.4 Shire Pharmaceuticals
9. Conclusions of the Study
9.1 The IBD Drugs Market Will Expand from 2017 to 2027
9.2 Aminosalicylates and Other Non-Biologic Treatments
9.3 Biological Treatments Dominate the Market
9.4 Improvements Needed in IBD Therapy
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis
Table 2.2 Worldwide Prevalence Rates for IBD, 2016
Table 2.3 Worldwide Incidence Rates for IBD, 2016
Table 2.4 Geographical Variations in the Incidence of IBD, 2016
Table 2.5 Other Drug Types Used to Treat IBD, 2016
Table 2.6 Treatment Protocol for IBD, 2016
Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market
Shares (%) by Segment, 2016 and 2017
Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
8. www.visiongain.com
Contents
Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%),
CAGR (%), 2016-2027
Table 3.4 Global IBD Drug Market Drivers and Restraints 2017-2027
Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%),
CAGR (%), 2016-2027
Table 3.6 Global Biologic Therapies Drivers and Restraints, 2017-2027
Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR
(%), CAGR (%), 2016-2027
Table 3.8 Global Aminosalicylates Drivers and Restraints, 2017-2027
Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%),
CAGR (%), 2016-2027
Table 3.10 Global Antibiotics Drivers and Restraints, 2017-2027
Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR
(%), CAGR (%), 2016-2027
Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027
Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m),
AGR (%), CAGR (%), 2016-2027
Table 3.14 Global Immunomodulators Drivers and Restraints, 2017-2027
Table 4.1 Leading IBD Treatments by Revenue ($m), 2016
Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2016-2027
Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 4.4 Drivers and Restraints for Humira, 2017-2027
Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.6 Drivers and Restraints for Remicade, 2017-2027
Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.8 Drivers and Restraints for Asacol, 2017-2027
Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
9. www.visiongain.com
Contents
Table 4.10 Drivers and Restraints for Pentasa, 2017-2027
Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.12 Drivers and Restraints for Lialda, 2017-2027
Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.14 Drivers and Restraints for Tysabri, 2017-2027
Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.16 Drivers and Restraints for Xifaxan, 2017-2027
Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.18 Drivers and Restraints for Cimzia, 2017-2027
Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.20 Drivers and Restraints for Entocort, 2017-2027
Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.22 Drivers and Restraints for Neoral, 2017-2027
Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.24 Drivers and Restraints for Medrol, 2017-2027
Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.26 Drivers and Restraints for Canasa, 2017-2027
Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.28 Drivers and Restraints for Apriso, 2017-2027
Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 4.30 Drivers and Restraints for Azulfidine, 2017-2027
10. www.visiongain.com
Contents
Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.32 Drivers and Restraints for Entyvio, 2017-2027
Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.34 Drivers and Restraints for Simponi, 2017-2027
Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-
2027
Table 4.36 Drivers and Restraints for Uceris, 2017-2027
Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2016
Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%),
2016-2021
Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%),
2021-2027
Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2016-2027
Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR
(%), 2016-2021
11. www.visiongain.com
Contents
Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR
(%), 2021-2027
Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2016-2027
Table 6.1 Key Patent dates for marketed and pipeline products
Table 6.2 Selected IL Inhibitors in Clinical Development, 2016
Table 6.3 Selected CAM Inhibitors in Clinical Development, 2016
Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2016
Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2016
Table 6.6 Selected JAK Inhibitors in Clinical Development, 2016
Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2016
Table 6.8 Selected Other Classes in Clinical Development, 2016
Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug
Market, 2016
Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug
Market, 2016
Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares
(%), 2016
Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2016
Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2016
Table 8.4 Allergan Revenues ($m) and Market Share (%), 2016
Table 8.5 Shire Revenues ($m) and Market Share (%), 2016
Table 9.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%)
by Product Category, 2016, 2021, 2027
17. www.visiongain.com
Contents
Pluristem Therapeutics
Quest Diagnostics
Ranbaxy Laboratories
Receptos
RedHill Biopharma
Reliance Life Sciences
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus
Sequella
Shire Pharmaceuticals
Sigmoid Pharma
Soligenix
SonarMD
Takeda Pharmaceuticals
Teva Pharmaceutical Industries
TiGenix
Toray Industries
TxCell
UCB
Valeant
Warner Chilcott
Zydus Cadila
List of Organisations Mentioned in the Report
Center for Human Disease Research, Leiden
Centrale Commissie Mensgebonden Onderzoek (CCMO)
Centres for Disease Control and Prevention (US)
Crohn’s and Colitis Foundation of Canada
18. www.visiongain.com
Contents
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Georgia State University
Hebrew University of Jerusalem
Institut National de la Santé et de la Recherche Médicale (INSERM)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Karolinska Institute
National Health Service (UK NHS)
National Institute for Health and Care Excellence (UK NICE)
National Institutes of Health (US NIH)
Servicio Sanitario Nazionale (SSN, Italy)
The Crohn’s and Colitis UK Foundation
The European Federation of Crohn's and Ulcerative Colitis Associations
19. Page 60www.visiongain.com
Global Inflammatory Bowel Diseases (IBD) Drug
Market Forecast 2017-2027: Aminosalicylates,
Antibiotics, Corticosteroids, Immunomodulators,
Biologics, Crohn’s Disease, Ulcerative Colitis
Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027
The consensus regarding treatment with these agents is that they should be tapered once
remission has been induced. Corticosteroids do not have a role in maintaining remission.
Patients who are concerned about immunosuppressive therapies, including immunomodulators or
anti–tumour necrosis factor (TNF) agents, should be educated about the potential greater
incidence of complications occurring with long-term steroid use and with undertreated disease.
Patients with prolonged use of steroids may also require ophthalmologic examination because of
the risk of development of glaucoma and cataracts.
Periodic assessment of bone mineral density is recommended for patients taking steroids for more
than 3 months. Agents used for osteoporosis prevention and treatment are useful for preventing
the bone loss associated with corticosteroid use.
Intravenous corticosteroids are often used for patients who are severely ill and hospitalized; few
data have been published on the optimum dosage of IV or oral corticosteroids. The upper end of
dosing generally includes IV methylprednisolone at 20 mg every 6 hours or IV hydrocortisone at
100 mg every 8 hours. Typically, once a clinical response is observed (usually within 3-5 days), the
dose of the IV corticosteroid can be tapered. Before hospital discharge, conversion to an oral
corticosteroid is made with dosage tapering in an outpatient setting.
• Act rapidly to control
symptoms, hence considered
to be very effective in this
capacity
• Can be administered through
various different routes,
depending on patient’s
condition
Drivers Restraints
• Only used to control flare ups
of IBD, and not used as a
maintenance therapy
• Associated with reported side
effects when used over long
periods of time
Source: visiongain 2017
21. Page 133www.visiongain.com
Global Inflammatory Bowel Diseases (IBD) Drug
Market Forecast 2017-2027: Aminosalicylates,
Antibiotics, Corticosteroids, Immunomodulators,
Biologics, Crohn’s Disease, Ulcerative Colitis
The Italian market is restricted by the poor economic environment. Servicio Sanitario Nazionale
(SSN), the Italian healthcare system (a universal healthcare system similar to the UK’s National
Health Service), is challenged by decreasing budgets, increased focus on chronic diseases and
diseases related to the elderly. Austerity measures implemented in June 2010 introduced
reimbursement limits for generics, price cuts, requirements for doctors to prescribe the cheapest
generic where possible, a reduction in the pharmacy profit margin of the end price of a drug, and a
levy on drug manufacturers set at 1.83% of the price of the drug to be paid to regional health
authorities. Further regulation was passed in March 2012, and visiongain believes more changes
are likely to follow in the next ten years as the Italian government struggles to contain healthcare
spending.
5.5 IBD Drug Markets in BRIC Countries – Taking More
Market Share
The BRIC nations had a combined IBD drug market value of $949m in 2016, or 11% of the global
market. In addition, the market in these countries is expected to grow at a comparable rate to other
0
100
200
300
400
500
600
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenue($m)
Figure 5.10 Italian IBD Drug Market Forecast ($m), 2016-2027
Source: visiongain 2017